Published in Oncotarget on May 10, 2017
Cancer-related inflammation. Nature (2008) 34.21
Stat3 as an oncogene. Cell (1999) 17.39
STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer (2009) 15.45
Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity (1999) 7.78
gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell (2009) 6.26
Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer (2008) 5.65
The epidemiology of cholangiocarcinoma. Semin Liver Dis (2004) 5.59
Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene (2000) 5.39
Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology (2001) 5.12
Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer (2014) 3.70
Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut (2001) 3.45
Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci U S A (2000) 3.44
Protein tyrosine phosphatases in signal transduction. Curr Opin Cell Biol (1997) 3.35
Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci U S A (2001) 3.29
Risk factors for cholangiocarcinoma. Hepatology (2011) 3.27
Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst (2006) 3.17
Burden of digestive diseases in the United States Part III: Liver, biliary tract, and pancreas. Gastroenterology (2009) 3.03
Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol (2002) 2.70
Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res (2014) 2.51
Cholangiocarcinoma: lessons from Thailand. Curr Opin Gastroenterol (2008) 2.44
Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res (2002) 2.41
Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes. Oncogene (2007) 2.14
Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. J Hepatol (2011) 2.12
Cholangiocarcinoma: current concepts and insights. Hepatology (2003) 1.96
An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage. Cancer Res (2000) 1.78
Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol (2012) 1.74
Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling? Cell Div (2010) 1.70
Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes. J Hepatol (2005) 1.69
Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2. Structure (1998) 1.67
Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells. Breast Cancer Res (2013) 1.67
Liver cancer in Thailand. I. A case-control study of cholangiocarcinoma. Int J Cancer (1991) 1.55
Human biliary epithelial cells secrete and respond to cytokines and hepatocyte growth factors in vitro: interleukin-6, hepatocyte growth factor and epidermal growth factor promote DNA synthesis in vitro. Hepatology (1994) 1.49
Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. Hepatology (2009) 1.49
Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood (2000) 1.47
Serum and bile markers for cholangiocarcinoma. Semin Liver Dis (2004) 1.46
Genetic and environmental determinants of risk for cholangiocarcinoma via Opisthorchis viverrini in a densely infested area in Nakhon Phanom, northeast Thailand. Int J Cancer (2005) 1.45
Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. Cancer Res (2001) 1.45
Advanced periductal fibrosis from infection with the carcinogenic human liver fluke Opisthorchis viverrini correlates with elevated levels of interleukin-6. Hepatology (2009) 1.37
Crystal structure of human protein-tyrosine phosphatase SHP-1. J Biol Chem (2002) 1.30
Crystal structure of the catalytic domain of protein-tyrosine phosphatase SHP-1. J Biol Chem (1998) 1.18
Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma. Hepatology (2013) 1.10
Tumor suppressor gene methylation in follicular lymphoma: a comprehensive review. Mol Cancer (2006) 1.00
SOCS1 and SHP1 hypermethylation in mantle cell lymphoma and follicular lymphoma: implications for epigenetic activation of the Jak/STAT pathway. Leukemia (2004) 0.99
Loss of SHP-1 tyrosine phosphatase expression correlates with the advanced stages of cutaneous T-cell lymphoma. Hum Pathol (2007) 0.99
Crystal structure of human protein tyrosine phosphatase SHP-1 in the open conformation. J Cell Biochem (2011) 0.96
RFX1-dependent activation of SHP-1 induces autophagy by a novel obatoclax derivative in hepatocellular carcinoma cells. Oncotarget (2014) 0.89
SHP-1 is a target of regorafenib in colorectal cancer. Oncotarget (2014) 0.88
Cucurbitacin B, a small molecule inhibitor of the Stat3 signaling pathway, enhances the chemosensitivity of laryngeal squamous cell carcinoma cells to cisplatin. Eur J Pharmacol (2010) 0.84
STATs profiling reveals predominantly-activated STAT3 in cholangiocarcinoma genesis and progression. J Hepatobiliary Pancreat Sci (2014) 0.80
The tyrosine 343 residue of nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) is important for its interaction with SHP1, a cytoplasmic tyrosine phosphatase with tumor suppressor functions. J Biol Chem (2010) 0.78
Dovitinib Acts As a Novel Radiosensitizer in Hepatocellular Carcinoma by Targeting SHP-1/STAT3 Signaling. Int J Radiat Oncol Biol Phys (2016) 0.76
Protein tyrosine phosphatase 1B dephosphorylates PITX1 and regulates p120RasGAP in hepatocellular carcinoma. Hepatology (2016) 1.41
Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A. Oncotarget (2015) 0.89
RFX1-dependent activation of SHP-1 induces autophagy by a novel obatoclax derivative in hepatocellular carcinoma cells. Oncotarget (2014) 0.89
Pharmacological Targeting SHP-1-STAT3 Signaling Is a Promising Therapeutic Approach for the Treatment of Colorectal Cancer. Neoplasia (2015) 0.87
STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma. Clin Cancer Res (2014) 0.83
Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity. J Hepatol (2014) 0.83
Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells. Oncotarget (2016) 0.82
A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy. Cancer Lett (2015) 0.78
Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer. Oncotarget (2016) 0.78
Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis. Sci Rep (2016) 0.77
In vitro and in vivo activity of a novel sorafenib derivative SC5005 against MRSA. J Antimicrob Chemother (2015) 0.77
Dovitinib Acts As a Novel Radiosensitizer in Hepatocellular Carcinoma by Targeting SHP-1/STAT3 Signaling. Int J Radiat Oncol Biol Phys (2016) 0.76
Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells. Oncotarget (2016) 0.76
Urolithin A suppresses the proliferation of endometrial cancer cells by mediating estrogen receptor-α-dependent gene expression. Mol Nutr Food Res (2016) 0.75
Protein tyrosine phosphatase 1B targets PITX1/p120RasGAP thus showing therapeutic potential in colorectal carcinoma. Sci Rep (2016) 0.75
SH2 domain-containing phosphatase 1 regulates pyruvate kinase M2 in hepatocellular carcinoma. Oncotarget (2016) 0.75
Carfilzomib induces leukaemia cell apoptosis via inhibiting ELK1/KIAA1524 (Elk-1/CIP2A) and activating PP2A not related to proteasome inhibition. Br J Haematol (2017) 0.75
Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma. Oncotarget (2017) 0.75
Corrigendum to "Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma". J Hepatol (2017) 0.75
The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells. Exp Mol Med (2017) 0.75
Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells. Mol Oncol (2017) 0.75
Erratum to: Corrigendum to "Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma". J Hepatol (2017) 0.75
Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6 independent manner. Mol Oncol (2017) 0.75